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Abstract
Background: Prospective, randomized, pilot clinical study was conducted to evaluate the beneficial effects of
inositol hexaphosphate (IP6) + Inositol in breast cancer patients treated with adjuvant therapy.
Patients and methods: Patients with invasive ductal breast cancer where polychemotherapy was indicated were
monitored in the period from 2005-2007. Fourteen patients in the same stage of ductal invasive breast cancer
were involved in the study, divided in two randomized groups. One group was subjected to take IP6 + Inositol
while the other group was taking placebo. In both groups of patients the same laboratory parameters were
monitored. When the treatment was finished, all patients have filled questionnaires QLQ C30 and QLQ-BR23 to
determine the quality of life.
Results: Patients receiving chemotherapy, along with IP6 + Inositol did not have cytopenia, drop in leukocyte and
platelet counts. Red blood cell counts and tumor markers were unaltered in both groups. However, patients who
took IP6 + Inositol had significantly better quality of life (p = 0.05) and functional status (p = 0.0003) and were able
to perform their daily activities.
Conclusion: IP6 + Inositol as an adjunctive therapy is valuable help in ameliorating the side effects and preserving
quality of life among the patients treated with chemotherapy.
Introduction
Breast cancer is the most common cancer in women
worldwide. Around 1.15 million cases were recorded in
2002, representing 23% of all female and 11% overall can-
cers [1]. Breast cancer incidence rates for 2002 vary inter-
nationally by more than 25-fold, ranging from 3.9 cases
per 100 000 in Mozambique to 101.1 in the US, in part
reflecting low screening rates and incomplete reporting
in developing countries [2]. Breast cancer is fatal in
almost half of all cases. It is the leading cause of cancer
death from cancer among woman worldwide, accounting
for 16% of cancer deaths in adult women [1,2].
Depending on the stage of breast cancer, the treat-
ment is carried out by surgery, chemotherapy, ionizing
radiation, hormone therapy and supportive measures
that aim to reduce the side effects of treatment. Most
patients are treated with chemotherapy in order to pre-
vent the systemic dissemination of basic diseases.
Patients are subjected to polychemotherapy - combina-
tion of three different drugs which are extremely aggres-
sive and hard to bear. There are several protocols used
in the treatment of breast cancer - FEC, FAC and CMF;
FEC is the most frequently used protocol. Side effects of
polychemotherapy (nausea, vomiting, loss of body
w e i g h t ,h a i rf a l lo u t ,i n s o m n i a ,d e p r e s s i o n ,d i s o r d e r si n
blood counts) appear in majority of patients and are the
most common reasons for stopping the treatment.
About 10% of patients interrupt the treatment which
increases the risk of the appearance of distant metasta-
sis, and reduces their chances for healing.
Inositol hexaphosphate (IP6) is a naturally occuring
polyphosphorylated carbohydrate, present in almost all
plant and mammalian cells, where it is important in reg-
ulating vital cellular functions such as signal transduc-
tion, cell proliferation and differentiation [3,4]. For a
long time, IP6 has been recognized as a strong
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any medium, provided the original work is properly cited.antioxidant. Recently, a striking anticancer effect of IP6
was demonstrated in different experimental models
[3-14]. Inositol is also a natural constituent possesing
moderate anticancer activity [3,4]. However, it was
shown that inositol potentiates both the antiproliferative
and antineoplastic effects of IP6 in vivo, and that the
combination of IP6 and inositol was significantly better
in different cancers (colon, breast and metastatic lung
cancer model) than was either one alone [3,4]. Due to
its strong antioxidant activity, and health beneficial
effects, such as immune stimulation, prevention of kid-
ney stone formation and hypocholesterolemic effect, IP6
+ Inositol is available as dietary supplement.
Current cancer treatment recognizes the importance
of combination therapy in order to increase efficacy and
decrease side effects of conventional chemotherapy. It
has been shown in vitro that IP6 acts synergistically with
doxorubicin and tamoxifen, being particularly effective
against estrogen receptor-negative and doxorubicin-
resistant breast cancer cell lines [15]. Furthermore, sev-
eral case studies have shown that when IP6 and inositol
were given in combination with chemotherapy, side
effects of chemotherapy were diminished and patients
were able to perform their daily activities [16-18]. Based
on these properties, this study has been designed to
evaluate in a small controlled clinical trial if the combi-
nation of IP6 + Inositol and traditional chemotherapy
will increase efficacy and decrease side effects of che-
motherapy, and in particular if the IP6 + Inositol will be
able to improve the quality of life in patients undergoing
the treatment for breast cancer.
Materials and methods
Study Population
In order to test the effectiveness of IP6 +I n o s i t o li n
improving the quality of life of patients who are treated
for breast cancer, we have conducted a prospective, ran-
domized, controlled clinical study with the tested (IP6 +
Inositol Group) and control (Placebo Group) groups of
patients. This study was approved by the ethics commit-
tee of the General Hospital, Zadar. Written informed
consent was obtained from all participants. The study
included 14 patients with ductal invasive breast cancer
subjected to surgery and with histological features and
stage of tumor that indicated polychemotherapy. All
patients received the FEC polychemotherapy protocol in
six cycles. Patients receiving neoadjuvant chemotherapy
were not included in the study.
Tested group consisted of 7 patients, average age 56
years (26-76), who were given IP6 + Inositol (IP6 Interna-
tional Inc., Melbourne, FL, USA) per os in the form of
powder in the daily dosage of 6 g, divided in 2 doses, start-
ing from the first postoperative day, every day until the
end of treatment (6 months). The control group consisted
of 7 patients, who were treated for ductal invasive breast
cancer of the same characteristics as the tested group. The
control group was given placebo (Vitamin C) of the same
look and consistency as IP6 + Inositol, in the same dosage
(6 g) until the end of treatment (6 months).
Study Procedures
At the end of treatment, all patients have filled the
questionnaires QLQ-30 and QLQ-BR23 from European
organization for testing the treatment of cancer
(EORTC) [19,20]. The questions in questionnaire were
divided into two scales, the functional and symptomatic.
Functional scale contains questions about the physical,
emotional, cognitive, social and sexual functions. Each
group has a range of responses matching from 0-100,
where 100 represents the maximum compatibility with the
offered answers, and 0 represents the complete lack of
compatibility.
Symptomatic scale contains questions about side
effects of treatment, such as the general bad condition,
nausea, vomiting, diarrhea, constipation, pain, insomnia,
loss of appetite, loss of body weight, hair loss, increase
body temperature and the operating complications of
treatment. Replies from symptomatic scale are evaluated
with the scale from 0-100, where 100 represents maxi-
mally positive personal experience with total quality of
life, and 0 represents maximally negative personal
experience of the quality of life.
Both groups of patients were monitored with the fol-
lowing laboratory parameters: total blood cell counts
(TBC), CEA, CA 15-3, LDH, AST, ALT, AP, bilirubin,
urea, creatinin and electrolytes. The testing was done at
the first day of therapy, a month after, and at the the
end of treatment.
For the processing of data obtained from the question-
naires, the QLQ-C30 SC (scoring manual), also pro-
duced by EORTC was utilized. The results were tested
for significancy with the Student t-test for small samples
(dependents and independents), and the p value of <
0.05 was considered significant.
Results
All 14 patients involved in the study were regularly taking
IP6 + Inositol or placebo during 6 months. Not a single
patient interrupted chemotherapy. The average age of life
of patients who have taken IP6 + Inositol was 56.2 years
(26-76), while in the group of patients who had taken pla-
cebo average age of life was 59 years (42-77).
The results of questionnaires about the quality of life
(EORTC)
Personal assesment of quality of life
The average total personal experience with the quality of
life was given in Table 1. Results of testing show that
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significantly higher qualityo fl i f et h a np a t i e n t sw h o
were taking placebo (78.3 compared to 48.4; p = 0.05).
Functional scale (FS)
Answering questions about certain functions in everyday
life, the average score was 87.9 in patients who have
taken IP6 + Inositol, while in patients who have taken
placebo, the average score on the functional scale was
56.3 (p = 0.0003) (Table 2). The difference between the
average scores between the two groups was statistically
significant, showing that that the functional status of
patients who were taking IP6 + Inositol in addition to
chemotherapy was significantly better preserved, in rela-
tion to the control group.
Simptomatic scale (SS)
Among the patients who where taking IP6 +I n o s i t o l ,
the average score of answers on questions about the
symptomatic scale was 13.5, while that score in the con-
trol group was 33.8. The diference of the average scores
between two groups is statistically significant (p = 0.04)
(Table 3).
Results of laboratory tests
Before treatment, the average number of leukocytes in
the group of patients who were taking IP6 +I n o s i t o l
was 6.66 (5.1-7.7) × 10
9/L, and after the treatment was
6.92 (3.8-9.1) × 10
9/L, an average increase of 0.26. In
the group of patients who were on placebo, the average
number of leukocytes before treatment was 7.53 (6.2-
10.4) × 10
9/L and 4.36 (1,18-6.5) × 10
9/L after the treat-
ment; an average decrease of 3.17. In the control group
of patients there was a statistically significant fall in the
number of leukocytes after treatment compared to the
number of leukocytes before treatment (p = 0.01), while
in the experimental group on IP6 + Inositol, not only
that the number of leukocytes did not change (p =
0.75), but it was even slightly increased (Table 4).
The average number of platelets before treatment was
229.57 (204-296) × 10
9/L in a group of patients who
were taking IP6 + Inositol, while after the treatment it
was 231.86 (182-322)× 10
9/L, representing an increase
of 2.29 × 10
9/L platelets. In the control group, the aver-
age number of platelets before the treatment was 272.71
(176-525) × 10
9/L, while after the treatment it was
205.00 (85-357) × 10
9/L, representing a a drop of 67.71
×1 0
9/L (p = 0.05). Drop in the number of platelets in
the control group of patients was statistically significant,
while the number of platelets in the experimental group
remained the same (Table 4).
In the IP6 + Inositol group, the red bloood cell counts
were 4.23 (3.56-5.22) × 10
12/L and the hemoglobin level
was 127.00 (110-151) g/L before treatment, while after
the treatment the erythrocytes were 4.48 (4.08-4.78) ×
10
12/L and the hemoglobin level was 135.86 g L, repre-
senting an increase of 0.25 in the number of erythro-
cytes and 8.86 g/L in the hemoglobin level, although not
significant. In the control group of patients the average
number of erythrocytes before the treatment amounted
to 4.45 × 10
12/L, and 4.03 × 10
12/L after the treatment,
while the hemoglobin level prior to treatment was
122.00 (103-142) g/L and 119.43 (106-135) g/L after
treatment, which represented a decrease of 0.4 in the
average number of erythrocytes and decrease of 2.57 in
the hemoglobin level. Changes in red blood cell counts
and in the hemoglobin levels are not statistically signifi-
cant for either group. These relations are evident from
the Table 4.
There were no significant changes in tumor markers
CEA and CA 15-3 during the treatment in both groups.
For CEA, preoperative average value in the IP6 + Inosi-
tol group was 3.01 ng/mL (1.0-6.7), and postoperative
value was 3.15 ng/mlL (1.5-6.9), which amounted to a
nonsignificant average increase of 0.14 ng/mL (p =
0.39). In the control group of patients, preoperative
average value for CEA was 2.40 ng/mL (1.2-5.3), while
the postoperative average CEA value was 2.48 ng/mL,
representing an average increase of 0.08 ng/mL (p =
0.87) (Table 5). Preoperative average value of CA 15-3
in the IP6 + Inositol group was 13.05 U/mL (9.2-16.3),
postoperative 13.80 U/mL (10.3-17.2), which was an
increase of 0.75 U/mL (p = 0.08). In the control group,
the average preoperative value for CA 15-3 was 26.27
U/mL ((12.7-49.6) and postoperative value was 27.41 U/
Table 1 Patients Personal Assessment of the Quality of
Life
Quality of Life
Patients Mean ± SD p value
Placebo Group 48.43 ± 28.96 0.05
IP6 + Inositol Group 78.33 ± 21.60
Table 2 Patients Personal Assessment of their Functional
Status
Functional Status
Patients Mean ± SD p value
Placebo Group 56.29 ± 15.32 0.0003
IP6 + Inositol Group 87.94 ± 6.94
Table 3 Patients Personal Assessment of Side Effects of
Therapy (Symptomatic Scale)
Clinical Symptoms of Side Effects of Therapy
Patients Mean ± SD p value
Placebo Group 33.81 ± 18.12 0.04
IP6 + Inositol Group 13.51 ± 9.98
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0.86) (Table 5).
Other laboratory parameters that were monitored dur-
ing the treatment (LDH, AST, ALT, AP, bilirubin, urea,
creatinine, and electrolytes) were stable in both groups
of patients and there were no deviations from the refer-
ence value.
Discussion
IP6 has been known for a long time for its beneficial
effects, including boosting immune system, preventing
kidney stone formation and lowering serum cholesterol
[3,4]. Additionally, IP6 has shown a significant antican-
cer effect against different experimental cancers [3-15].
For some time, IP6 is available as a dietary supplement.
Although few case studies in which IP6 plus inositol was
given in combination with chemotherapy clearly showed
encouraging data, organized, controlled, randomized
clinical studies were never organized [16-18]. Therefore,
this study conducted at the Department of Surgery,
General Hospital, Zadar on the group of voluntary
patients who were treated for breast cancer, is the first
study of its kind in the world. From this small clinical
testing we concluded that IP6 + Inositol was able to
improve the quality of life of breast cancer patients
undergoing chemotherapy compared to control, placebo
group with the same histological type of cancer and the
therapeutic protocol.
It is difficult to be objective and to numerically
express the quality of life of individual patients or
groups of patients in order to compare the quality of
life of another patient, because it depends on a number
of parameters. The European Association for research
and treatment of cancer (EORTC) has developed ques-
tionnaires for assessing the quality of life of patients
which have fallen ill from cancer, and thus tried to com-
pare objectively the quality of life that we utilized. Our
results show that patients who were taking IP6 +I n o s i -
tol in combination with chemotherapy, had overall sta-
tistically significantly better quality of life than patients
who were on placebo. Analyzing the answers to ques-
tions about the side effects of treatment and symptoms
of disease, we have seen that the frequency and intensity
of side effects associated with patients who were taking
IP6 + Inositol were statistically significantly lower in
comparison to patients who were taking placebo.
Drugs that are implemented in chemotherapy are agres-
sive and have impact to the tumor cells as well as to the
cells in the blood. Most patients who are undergoing che-
motherapy have some anomalies in their complete blood
count, primarily in the number of leukocytes and plate-
letes. Our results show that patients who have taken IP6 +
Inositol did not show drop in the number of leukocytes
and plateletes, on the contrary, these were even slightly
Table 4 Change in Complete Blood Cell Count Values
Blood Cells Placebo Group
(Mean ± SD)
IP6 + Inositol Group
(Mean ± SD)
White Blood Cell Count (×10
9/L) Before Treatment 7.53 ± 1.50 6.66 ± 0.96
After Treatment 4.36 ± 1.80 6.92 ± 2.12
p value 0.01 0.75
Platelet Count
(×10
9/L)
Before Treatment 272.71 ± 114.86 229.57 ± 31.81
After Treatment 205.00 ± 90.56 231.86 ± 47.33
p value 0.05 0.92
Red Blood Cell Count
(×10
12/L)
Before Treatment 4.45 ± 0.71 4.23 ± 0.71
After Treatment 4.05 ± 0.52 4.48 ± 0.23
p value 0.23 0.39
Hemoglobin
(g/L)
Before Treatment 122.00 ± 17.28 127.00 ± 19.94
After Treatment 119.43 ± 10.78 135.86 ± 10.16
p value 0.68 0.36
Table 5 Values of Tumor Markers CEA and CA15-3
Tumor
Markers
Placebo
Group
(Mean ± SD)
IP6 + Inositol
Group
(Mean ± SD)
CEA
(ng/mL)
Before
Treatment
2.40 ± 1.53 3.01 ± 1.80
After Treatment 2.48 ± 1.27 3.15 ± 1.85
p value 0.87 0.39
CA 15-3
(kU/L)
Before
Treatment
26.27 ± 15.20 13.05 ± 2.35
After Treatment 27.41 ± 17.28 13.80 ± 2.67
p value 0.86 0.08
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hemoglobin levels were also noticed in the IP6 + Inositol
group. Tumor markers, liver enzymes, bilirubin, urea,
creatinine and electrolytes were not disturbed in either
group during the 6-month period of treatment.
Although our clinical study was conducted on a small
number of patients, our results confirmed previous
observations and clearly demonstrated that IP6 +I n o s i -
tol when included in chemotherapy for breast cancer
significantly improved patients’ quality of life and pro-
tected patients from the loss in the number of leuko-
cytes and plateletes [16-18].
The question remains to what extent we can include
IP6 + Inositol in the therapeutic program for breast can-
cer. The dosage of 6 g daily represents a low dose level of
IP6 + Inositol. Extrapolated from animal data, in the
absence of a dose-determination study in humans, the
recommended prophylactic dosage of IP6 +I n o s i t o li s1 -
2 g/day and a cancer therapeutic dosage is 8-12 g/day [4].
Even though our dosage was low, its efficacy to diminish
the side effects of chemotherapy was significant.
Recent phase I study of inositol for lung cancer chemo-
prevention showed that in a daily dose of 18 g p.o. for 3
months, inositol was safe and well tolerated [21].
Recently it was reported that the combination of beta-
(1,3)/(1,6) D-glucan and IP6 was well tolerated and had
beneficial effect on hematopoesis in the treatment of
patients with advanced malignancies receiving che-
motherapy [22]. Although the results of our pilot studies
are encouraging, it is necessary to conduct further multi-
centric clinical testing on a larger number of patients for
further evaluation of the impact that IP6 +I n o s i t o lo n
the quality of life of patients treated from breast cancer.
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